Navigation Links
Insmed Announces Planned Departure Of Chief Financial Officer

MONMOUTH JUNCTION, N.J., July 30, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced that the Company's Executive Vice President & Chief Financial Officer, Kevin Tully, will be leaving the Company when his current contract expires on December 1, 2012 due to family reasons.  Insmed has begun its search to identify candidates to replace Mr. Tully in the CFO role. 

"I would like to thank Kevin for his considerable contributions to Insmed in the 11 years he has spent with the Company," said Timothy Whitten, Insmed's President and Chief Executive Officer. "He was instrumental in enabling the successful combination of Insmed and Transave, as well completing a number of other critical initiatives during his tenure.  We wish him well in all his future endeavors."

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on the development of innovative inhaled pharmaceuticals for the site-specific treatment of serious lung diseases.  Insmed's primary focus is on the development of inhaled antibiotic therapy delivered via proprietary advanced liposomal pulmonary technology in areas of high unmet need.  For more information, please visit

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to Mr. Tully's departure and the search for his replacement constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, delays in our ability to find a replacement for Mr. Tully.  Investors are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release.  We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

Investor Relations Contact:
Brian Ritchie – FTI Consulting

Media Contact:
Irma Gomez-Dib – FTI Consulting

SOURCE Insmed Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Insmed to Host 2012 Second Quarter Earnings Conference Call
2. Insmed To Present At JMP Securities 7th Annual Healthcare Conference
3. Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease
4. Insmed Announces First Quarter 2012 Financial Results
5. Insmed Incorporated Announces Lifting of Clinical Hold by U.S. Food and Drug Administration on ARIKACE® in Cystic Fibrosis Patients With Pseudomonas Lung Infections
6. Insmed to Host 2012 First Quarter Earnings Conference Call
7. Absorption Systems announces novel test platform for interactions with the BCRP transporter
8. Novogen Announces Merger Agreement With Kai Medical And Distribution Of Mei Pharma Shares
9. Aethlon Medical Announces the Appointment of Thomas V. Wornham and Philip A. Ward to its Board of Directors
10. IRIDEX Announces Second Quarter 2012 Conference Call and Release Date
11. Gentris Corporation Announces Collaboration to Study Blood Stability
Post Your Comments:
(Date:11/25/2015)... Research and Markets ( ) has announced the ... to 2020" report to their offering. ... the total market share in 2014. The market for ... to growth at the highest CAGR between 2015 and ... fast growing water, industrial gas treatment, pharmaceutical, and food ...
(Date:11/24/2015)... DELHI , November 25, 2015 ... invoked due to repeated failure of IVF cycles. After ... Bhatia was totally dejected and had lost all hopes that she would be ... first Indian miracle child conceived after failure of over ... to abroad (UK) before they decided to take one last attempt ...
(Date:11/24/2015)... Nov. 24, 2015  Natera, Inc. (Nasdaq: ... genetic testing and the analysis of circulating ... present at the 27 th  Annual Piper ... 2015 at 1:00 p.m. ET.  Matthew Rabinowitz, Ph.D., CEO of ... business activities and financial outlook. ...
Breaking Medicine Technology:
(Date:11/25/2015)... Rouge, LA (PRWEB) , ... November 25, 2015 , ... ... in the United States District Court of Connecticut on behalf of a home health ... behalf of all current or former home health care workers employed by Humana, Inc., ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... is encouraging people across the country to celebrate their sobriety and show through ... to post “before and after” photos this Thanksgiving with the hashtag #FacesOfGratitude on ...
(Date:11/25/2015)... Florida (PRWEB) , ... November 25, 2015 , ... ... testing for physicians and athletic programs, launches new Wimbledon Athletics Facebook ... of testing young athletes for unsuspected cardiac abnormalities. About 2,000 people under the ...
(Date:11/25/2015)... ... November 25, 2015 , ... Smiles by Stevens is pleased to ... facial wrinkling. While many patients are aware of the benefits of Botox® in the ... to those suffering with discomfort, soreness, and pain as a result of Jaw Tension, ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... decades of music, friendships, and learning in its 65th Anniversary Brillianteen Revue, scheduled ... 5-6. , For 65 years, Brillianteen has been a treasured tradition ...
Breaking Medicine News(10 mins):